Segars J H, Marks M S, Hirschfeld S, Driggers P H, Martinez E, Grippo J F, Brown M, Wahli W, Ozato K
Laboratory of Molecular Growth Regulation, National Institute of Child Health and Human Development, Bethesda, Maryland 20892.
Mol Cell Biol. 1993 Apr;13(4):2258-68. doi: 10.1128/mcb.13.4.2258-2268.1993.
The retinoid X receptor beta (RXR beta; H-2RIIBP) forms heterodimers with various nuclear hormone receptors and binds multiple hormone response elements, including the estrogen response element (ERE). In this report, we show that endogenous RXR beta contributes to ERE binding activity in nuclear extracts of the human breast cancer cell line MCF-7. To define a possible regulatory role of RXR beta regarding estrogen-responsive transcription in breast cancer cells, RXR beta and a reporter gene driven by the vitellogenin A2 ERE were transfected into estrogen-treated MCF-7 cells. RXR beta inhibited ERE-driven reporter activity in a dose-dependent and element-specific fashion. This inhibition occurred in the absence of the RXR ligand 9-cis retinoic acid. The RXR beta-induced inhibition was specific for estrogen receptor (ER)-mediated ERE activation because inhibition was observed in ER-negative MDA-MB-231 cells only following transfection of the estrogen-activated ER. No inhibition of the basal reporter activity was observed. The inhibition was not caused by simple competition of RXR beta with the ER for ERE binding, since deletion mutants retaining DNA binding activity but lacking the N-terminal or C-terminal domain failed to inhibit reporter activity. In addition, cross-linking studies indicated the presence of an auxiliary nuclear factor present in MCF-7 cells that contributed to RXR beta binding of the ERE. Studies using known heterodimerization partners of RXR beta confirmed that RXR beta/triiodothyronine receptor alpha heterodimers avidly bind the ERE but revealed the existence of another triiodothyronine-independent pathway of ERE inhibition. These results indicate that estrogen-responsive genes may be negatively regulated by RXR beta through two distinct pathways.
视黄酸X受体β(RXRβ;H-2RIIBP)与多种核激素受体形成异源二聚体,并结合多个激素反应元件,包括雌激素反应元件(ERE)。在本报告中,我们表明内源性RXRβ有助于人乳腺癌细胞系MCF-7核提取物中的ERE结合活性。为了确定RXRβ在乳腺癌细胞中对雌激素反应性转录的可能调节作用,将RXRβ和由卵黄蛋白原A2 ERE驱动的报告基因转染到经雌激素处理的MCF-7细胞中。RXRβ以剂量依赖性和元件特异性方式抑制ERE驱动的报告基因活性。这种抑制在没有RXR配体9-顺式视黄酸的情况下发生。RXRβ诱导的抑制对雌激素受体(ER)介导的ERE激活具有特异性,因为仅在转染雌激素激活的ER后,在ER阴性的MDA-MB-231细胞中才观察到抑制。未观察到对基础报告基因活性的抑制。这种抑制不是由RXRβ与ER对ERE结合的简单竞争引起的,因为保留DNA结合活性但缺乏N端或C端结构域的缺失突变体未能抑制报告基因活性。此外,交联研究表明MCF-7细胞中存在一种辅助核因子,它有助于RXRβ与ERE的结合。使用RXRβ已知的异源二聚体伙伴进行的研究证实,RXRβ/三碘甲状腺原氨酸受体α异源二聚体可 avidly 结合ERE,但揭示了存在另一种不依赖三碘甲状腺原氨酸的ERE抑制途径。这些结果表明,雌激素反应性基因可能通过两种不同途径受到RXRβ的负调控。